LONDON:

Drugmaker Hikma Pharmaceuticals Plc said its core operating profit fell 14 percent to $176 million, hurt by lower contribution from specific market opportunities for its generics business.

The Jordanian company, which makes and markets branded and non-branded generic and injectable drugs, reported revenue of $882 million for six months ended June 30.

Hikma warned in August that fullyear core operating profit from its generics unit would be hurt by delayed approvals of new products and higherthan-expected costs.